News | May 29, 2015

Public-Private Partnership Restarting Mo-99 Production in U.S.

Cooperative R&D agreement will develop scalable standalone system for domestic production

May 29, 2015 — National Security Technologies LLC (NSTec) and Henderson, Nevada-based Global Medical Isotope Systems (GMIS) announced a public-private partnership agreement for research and development of an essential radioactive isotope used in millions of medical diagnostic imaging procedures annually.

Known primarily as the management and operations contractor for the Nevada National Security Site (NNSS), NSTec is leveraging its traditional national security role with the signing of its first cooperative research and development agreement (CRADA). The agreement describes NSTec's technical integration, modeling, materials and design support to GMIS's mission in the development and deployment of a ground-breaking approach to the production of the radioactive isotope molybdenum-99 (Mo-99).

By introducing a safe, decentralized, on-demand production system using non-enriched uranium, the two companies are answering a critical supply need of the medical imaging community. The United States terminated its domestic Mo-99 production in the 1990s, but continues to import the isotope from Canada and Europe. In addition, U.S. and global demand for Mo-99 has grown substantially in recent years, making easy and timely access to supplies of the isotope more important than ever.

The imaging isotope Technetium-99m (Tc-99m) is a decay by-product of Mo-99, and has a half-life of only about 6 hours. This unique physical characteristic makes Tc-99m the most widely used medical diagnostic isotope in nuclear medicine. Its short half-life allows it to be used in body-scanning procedures that collect data rapidly, but keeps total patient radiation exposure low — but it also makes keeping an inventory next to impossible. 

Presently, there are about 40 million imaging and diagnostic procedures performed worldwide per year, of which 80-85 percent use Tc-99m. Of those 40 million, more than 20 million are performed in North America, about 1.5 million in Canada, and approximately 15,000 in southern Nevada.

GMIS is currently developing a scalable standalone system to produce the isotope, allowing for custom deployments to other areas of the country.

The five-year CRADA calls for NSTec to provide technical integration, modeling, materials, and design support to GMIS's mission.  

NSTec also brings to the CRADA a staff of nuclear and health physicists, skilled physics and electronics technicians, a variety of radiological materials, and an extensive inventory of radiation detection equipment.

For more information: www.nstec.com

Related Content

ASRT Supports Radiopharmaceutical Reimbursement Bill
News | Radiopharmaceuticals and Tracers | August 02, 2019
The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure...
NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility
News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
Overlay Init